Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis

Código QR

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis

Dorothea Groß,1 Marc Childs,2 Jean-Marie Piaton3 1Ursapharm Arzneimittel GmbH, Saarbrücken, Germany; 2Laboratoires Delbert, Paris, 3Ophthalmic Practice, Domont, France Purpose: Comparison of efficacy and safety of 0.2% and 0.18% hyaluronic acid (HA) eye drops three times a day (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Groß D, Childs M, Piaton J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Dry eye hyaluronic acid ocular surface lesions ocular staining keratoconjunctivitis sicca Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/fa34ae3f6fab40f19d4ae5e588804afe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease
por: Friedman NJ, et al.
Publicado: (2016)

Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis
por: Groß D, et al.
Publicado: (2018)

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
por: Nebbioso M, et al.
Publicado: (2019)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
por: Hassan Sajjad Rathore, et al.
Publicado: (2021)

Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
por: Burillon C, et al.
Publicado: (2018)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard J, et al.
Publicado: (2021)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella P, et al.
Publicado: (2018)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Dry Eye Syndrome and Sicca Complex are Commonly Found in Patients with Postural Orthostatic Tachycardia Syndrome
por: Ho DS, et al.
Publicado: (2020)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins GW, et al.
Publicado: (2020)

Acupuncture and dry eye: current perspectives. A double-blinded randomized controlled trial and review of the literature
por: Dhaliwal DK, et al.
Publicado: (2019)

Molecular characterization of bacterial microbiota associated with infectious bovine keratoconjunctivitis in Michoacán, Mexico
por: Ana M. Ríos-Alanís, et al.
Publicado: (2020)

Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
por: Rush SW, et al.
Publicado: (2021)

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman LM, et al.
Publicado: (2020)

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation
por: Chávez-Mondragón E, et al.
Publicado: (2019)

Phytosome-hyaluronic acid systems for ocular delivery of L-carnosine
por: Abdelkader H, et al.
Publicado: (2016)

Ocular Trauma in Pediatric Age Group at a Tertiary Eye Care Center in Central Maharashtra, India
por: Madan AH, et al.
Publicado: (2020)

Epidemiology of Eye Injuries Resulting in Hospitalization, a Referral Hospital-Based Study
por: Choovuthayakorn J, et al.
Publicado: (2020)

Proton Sensing on the Ocular Surface: Implications in Eye Pain
por: Núria Comes, et al.
Publicado: (2021)

Effect of topical Mitomycin-C (0.01%) in treatment of severe vernal refractory keratoconjunctivitis
por: SMH Emad, et al.
Publicado: (2005)

Protecting the Ocular Surface in Cataract Surgery: The Efficacy of the Perioperative Use of a Hydroxypropyl Guar and Hyaluronic Acid Ophthalmic Solution
por: Favuzza E, et al.
Publicado: (2020)

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
por: Meier E, et al.
Publicado: (2017)

Vernal keratoconjunctivitis
por: Addis H, et al.
Publicado: (2018)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo H, et al.
Publicado: (2016)

RELATIONSHIP OF SCREEN HOURS WITH DIGITAL EYE STRAIN: A CROSS SECTIONAL SURVEY FROM TEENAGERS
por: Saira Maroof, et al.
Publicado: (2019)

A Comparative Study Between the Goldmann Applanation Tonometer and the Non-Contact Air-Puff Tonometer (Huvitz HNT 7000) in Normal Eyes
por: Stock RA, et al.
Publicado: (2021)

Evaluation of patients with dry eye for the presence of primary or secondary Sjӧgren’s syndrome
por: Abd-Allah NM, et al.
Publicado: (2019)

Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy
por: Brooks CC, et al.
Publicado: (2020)

Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye
por: Alexander Vaneev, et al.
Publicado: (2021)

Preliminary In Vivo Safety Evaluation of a Tacrolimus Eye Drop Formulation Using Hydroxypropyl Beta Cyclodextrin After Ocular Administration in NZW Rabbits
por: Mahmoudi A, et al.
Publicado: (2020)

Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use
por: Molina-Solana P, et al.
Publicado: (2020)

Eye wash water flow direction study: an evaluation of the effectiveness of eye wash devices with opposite directional water flow
por: Fogt JS, et al.
Publicado: (2018)

Cross-linked hyaluronic acid gel occlusive device for the treatment of dry eye syndrome
por: Fezza JP
Publicado: (2018)

Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
por: Shoughy SS, et al.
Publicado: (2016)

Detección de lesiones oculares en niños seropositivos para Toxocara canis
por: Sánchez T,Juan E, et al.
Publicado: (2011)

Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
por: McDonald MB, et al.
Publicado: (2018)

Patient-reported severity of dry eye and quality of life in diabetes
por: Yazdani-Ibn-Taz MK, et al.
Publicado: (2019)

Gelatin–epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief
por: Huang HY, et al.
Publicado: (2018)